Loading...
Loading...
In a company update published earlier today, Ladenburg Thalmann Financial Services reiterated its Buy rating and $7.75 price target for CryoLife, Inc.
CRY.
Ladenburg Thalmann said in its report “CryoLife expects 2012 revenue from HeRO sales to be between $2.5MM and $3.5MM. The transaction is expected to be $0.09-$0.10 dilutive to earnings in FY-2012, which includes non-recurring transaction and integration charges of between $0.06-$0.08, of which $0.04-$0.05 is expected during Q2-2012. We would also anticipate slightly higher R&D expense related to HeRO, as the device is currently being modified and enhanced through prototyping.”
CryoLife, Inc. closed yesterday at $4.93.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in